Dear HR community,

Dec 8, 2023, Aon plc, a leading global professional services firm, announced it has released the China Best ESG Employers Award list for 2023. The award recognizes businesses accelerating ESG practices while striving to enhance their employer value proposition beyond employee experience and engagement.

Ipsen China was awarded the Aon 2023 China’s Best ESG Employer Individual Award – Evolving Award among the total 225 participating companies.

“Ipsen China, adhering to its global ESG framework – Generation Ipsen, upholds the entrepreneurship with the mission of Put Ipsen at the center of China, put China at the center of Ipsen. Despite the challenges of internal business transformation and external market fluctuations, Ipsen China is committed to building organizational resilience through relentless efforts. It reflects Ipsen’s commitment to providing innovative drugs and treatment options to patients in China.” – Comments from Aon 2023 Best ESG Employer Award Ceremony

“This recognition affirms our steadfast commitment guided by global ESG framework “Generation Ipsen” to sustainability, responsibility, and making positive impact in the lives of patients and communities. It also witnesses our entrepreneurship and resilience with a mission to Put Ipsen at the center of China, put China at the center of Ipsen. Ipsen China remains dedicated to put patients at the heart of our strategy, pushing boundaries, contributing to positive impact on our people, patient, and society.” – Comments from Guillaume DELMOTTE, China General Manager.

As a century-old multinational biopharmaceutical company, Ipsen has always recognized our responsibility to positively create real impact on the local communities. Ipsen’s ESG philosophy, “Generation Ipsen”, is structured around four pillars (Patients, Employees, Environment, Governance) and guided by clearly defined objectives that help us focus on initiatives that will have the greatest impact on society. This philosophy touches every aspect of our business and allows every Ipsen employee to play a role in creating a positive impact.

• Patients

In 2021, Ipsen adjusted its strategy to focus on specialty pharmaceuticals, concentrating on three therapeutic areas: oncology, rare diseases, and neuroscience.

After the transformation, Ipsen is deeply committed to the China market and, with original mission of Patient Centricity, continues to invest in its R&D pipeline and supply chain to ensure continuous support for patients. At the same time, with the support of the local government and by strengthening the public healthcare environment, Ipsen is committed to improving the accessibility of its innovative products to more patients.

With continuous efforts, diseases covered by Ipsen’s rare disease product pipeline have been included in the 2nd Batch of RDL, which will be jointly issued by six departments, including the Healthcare Commission, in 2023. This will encourage the launch of new therapies in China and improve affordability for patients, and at the same time, it also confirms Ipsen’s exploration and breakthroughs in the field of specialty drugs as a company full of sense of responsibility and mission.

• People

During the transformation process, Ipsen employees were driven by a strong sense of mission to develop and explore their own strengths in order to successfully push forward the implementation of medicines and therapeutic programs that meet patients’ needs and bring breakthroughs to patients. Ipsen’s employees have demonstrated the execution, purpose driven, tenacity and entrepreneurial spirit, which has helped the company break through and smoothly transform its specialty drug business into a new stage of development.

Meanwhile, as a 100-year-old French biopharmaceutical company, the sustainable development of an enterprise should not only focus on its own sustained, stable and healthy development, but also create a collaborative, diversified and inclusive working environment, as well as dedicate to the development and cultivation of talents, which will be the determining factor for the enterprise to obtain long-term resilient development. Ipsen believes that whether you come from Generation X, Y or Z, we are all Generation Ipsen who create impact!

• Environment

Ipsen insists on being guided by the United Nations Sustainable Development Goals (SDGs) and contributing its part in creating a sustainable future. Ipsen joined the ‘1.5°C Temperature Limit Goal Initiative’ and the ‘Green Car’ program in 2021.

For two consecutive years, Ipsen China launched the CSR campaign ‘Beneficial Family, Walking Together’, realizing ‘One Egg’ through the online walking challenge, ‘Protecting Dongtan to protect the birds flying’ The support and landing of public welfare projects such as ‘One Egg’ and ‘Protect Dongtan for Birds’ have fully demonstrated the enthusiasm of Ipsen China’s employees, as well as their commitment and determination to protect the earth’s environment and practice a low-carbon life.

• Governance

Ipsen continuously improves its internal control and compliance management framework, including the establishment of an independent anti-corruption department, a compliance management committee, internal and external communication processes and systems, regular training, anti-corruption monitoring and an independent reporting mechanism. In December 2022, Ipsen China received ISO 37001 certification for its anti-corruption management system.

Ipsen is fully committed to its mission of providing medicines to improve the lives of patients in full compliance with applicable laws, regulations, and industry norms, as well as the highest ethical standards.

In the future, Ipsen will always be committed to implementing the ESG framework of ‘Generation Ipsen’, insisting on collaboration, precision, moving forward with resilience, and making breakthroughs to better benefit Chinese patients!

China HR Team